Spyre Therapeutics, Inc. (NASDAQ: SYRE) was founded in 2013. The company's original name was Aeglea BioTherapeutics, Inc., which was changed to its current name in November 2023. Headquartered in Waltham, Massachusetts, Spyre Therapeutics, Inc. is a pre clinical company with 30 full-time employeesBiotechnology Company, focusing on developing treatment methods for patients with inflammatory bowel disease (IBD).
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics focuses on developing next-generation therapies for IBD patients, including ulcerative colitis (UC) and Crohn's disease (CD).Spyre's new proprietary monoclonal antibody candidate product portfolio has the potential to address unmet needs in IBD care. If approved, Spyre believes that its candidate products may provide promising treatment options to help patients with IBD.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
Spyre Therapeutics developed SPY001, a human monoclonal immunoglobulin G1 antibody, which is designed to selectively bind to a4 ß 7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
Spyre Therapeutics is also developing SPY002, a human monoclonal antibody (mAb) candidate drug designed to bind to tumor necrosis factor like ligand 1A;SPY120 is a combination of SPY001 (anti a4 ß 7) and SPY002 (anti TL1A) antibodies, which is currently in the pre clinical research stage.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
In addition, other early projects of Spyre Therapeutics include SPY003, a monoclonal antibody against IL-23;SPY004,A novel mechanism of action (MOA) monoclonal antibody;SPY130,Combination of anti a4 ß 7 and anti IL-23 mAb;SPY230,Combination of anti TL1A and anti IL-23 mAb.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
On November 27, 2023, biotechnology companies in the development stageAeglea BioTherapeutics, Inc.(NASDAQ stock code: AGLE) announced that it will be renamed Spyre Therapeutics, Inc. From the opening on November 28, 2023, Spyre will be traded on NASDAQ with the stock code of "SYRE".This renaming was carried out after the company acquired the privately held Spyre Therapeutics, Inc. in June 2023.The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
Spyre Therapeutics, Inc. (SYRE) US equity investment
In June 2024, by opening an account at Home of American Stocks and merging 10000 Hong Kong dollars (HKD) into Long Bridge, you can get a lifetime free commission of [Hong Kong shares+American shares], and can also get up to 1100 Hong Kong dollars of stock coupons+an additional 88 yuan of JD Card (exclusive)+100 yuan of rebate (exclusive).Exclusive to American Stock House customers.Click to view details!
The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.htmlThe article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks-https://www.mg21.com/syre.html
two hundred and forty-nine million three hundred and forty-two thousand five hundred and nineteen
WeChat official account: Encyclopedia of US and Hong Kong stocks
WeChat search: mggbkqs
mggbkqs
This article is written byOriginated by American Stock HousePublished at 08:10:03, April 4, 2024
Original articles of American Stock House,Unauthorized reproduction is strictly prohibited。This article and all articles on this website are intended for information dissemination and sharing, and do not constitute an invitation, solicitation, suggestion, opinion or any guarantee for any securities, financial products or instruments. American Stock House does not endorse any companies, securities firms or financial products.There are risks in investment. Customers should weigh the risks they can bear and make investment judgments independently. If you have any questions, please consult independent professionals.Disclaimer